AAV pro­duc­er New­Bi­ologix emerges from stealth with $50M Se­ries A

An AAV-cen­tered biotech has come on­to the scene with $50 mil­lion in hand, look­ing to use an in-house plat­form to pro­duce a com­mon com­po­nent used in cell and gene ther­a­pies.

On Thurs­day, New­Bi­ologix an­nounced that it is work­ing on a DNA-based plat­form to ad­dress man­u­fac­tur­ing is­sues that come with de­vel­op­ing AAV vec­tors used in ad­vanced ther­a­pies. The Swiss com­pa­ny has come out of stealth with a $50 mil­lion Se­ries A.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER